Modélisation du poly-époxy DGEBA-EDA et de sa réactivité vis-à-vis du cuivre : approche expérimentale et numérique

Grâce à la métallisation de leur surface, des pièces en polymères peuvent substituer certains composants métalliques dans les industries de l'aérospatiale et du transport. Les polymères ont des masses volumiques plus faibles que les métaux et une réactivité chimique limitée, ce qui en fait des candidats idéaux pour les applications spatiales. En combinant techniques expérimentales et simulations numériques, nous avons étudié les mécanismes fondamentaux de la métallisation de surface d'un polymère poly-époxy (DGEBA / EDA). L'objectif de notre étude était de développer un modèle non empirique prenant en compte les mécanismes régissant la nucléation et la croissance des films minces métalliques. Notre groupe a une longue expérience des dépôts chimiques en phase vapeur, CVD. Mais cette technique n'a pas été choisie pour la métallisation de nos surfaces de polymères car les températures requises dans le réacteur étaient trop élevées. Comme alternative, nous avons effectué une évaporation sous ultravide de Cu à température ambiante, conduisant à une diffusion des atomes en phase gazeuse sans énergie cinétique. Les processus d'adsorption et de diffusion sont donc plus proches des conditions thermodynamiques associées aux calculs. Un protocole expérimental a été mis en place afin de créer une surface polymère chimiquement homogène présentant une faible rugosité. Le polymère obtenu a été caractérisé (i) par spectroscopie infrarouge à transformée de Fourier, pour déterminer le taux de polymérisation (supérieur à 90%), (ii) par calorimétrie différentielle à balayage pour obtenir la température de transition vitreuse (Tg) ( 118,1 °C), (iii) par microscopie à force atomique (AFM) pour estimer la rugosité de la surface (Ra ˜ 1 nm), et (iv) par spectroscopie de photoélectrons X (XPS) pour caractériser les liaisons chimiques de surface. La surface de polymère a ensuite été métallisée. Grâce à des analyses AFM, l'épaisseur du film mince a été estimée à 6 nm. Nous avons ensuite utilisé l'XPS pour caractériser les liaisons interfaciales Cu / Poly-époxy. Nous avons déduit de l'interprétation des spectres XPS que le Cu est adsorbé préférentiellement sur un atome d'oxygène spécifique du polymère. Pour identifier clairement ces sites d'adsorption de Cu, nous avons ensuite simulé les spectres XPS du polymère non revêtu, par des calculs quantiques, en utilisant un modèle moléculaire (dimère : 1 molécule de DGEBA liée à 1 molécule d'EDA). Les méthodes Hartree-Fock (HF) et de la théorie de la fonctionnelle de la densité (DFT) nous ont permis de simuler des spectres XPS pour la surface nue, en prenant en compte les effets d'état final et initial. Grâce à ces résultats, nous avons pu décomposer le spectre expérimental en 8 contributions, ce qui conduit à des résultats beaucoup plus précis que les résultats habituels obtenus par l'utilisation exclusive des expériences et de la littérature. Nous avons ensuite effectué des simulations de dynamique moléculaire classique (MD) pour passer d'un modèle moléculaire (dimère) à un modèle de polymère amorphe. Nous avons utilisé le champ de force Amber généralisé (GAFF) et nous avons développé un code de réticulation des molécules de monomères. Le système initial était un mélange stœchiométrique de molécules DGEBA et EDA qui a été équilibré à 700K. Lorsque l'équilibre a été atteint, certaines propriétés structurales (par exemple, la distribution des liaisons) ont été extraites des simulations NPT. À partir de ce mélange liquide de monomères, notre code de réticulation a identifié et relié les atomes réactifs (à une distance interatomique prédéfinie < 3 Å). Après chaque étape de polymérisation, le système a été rééquilibré à 700K (simulations NPT). Après plusieurs cycles de réticulation/simulation de dynamique moléculaire, nous avons pu atteindre un taux de polymérisation de 93% et la fonction de distribution radiale (RDF), la masse volumique (1.115 à 300K) et la température de transition vitreuse Tg (115,5 °C) ont été calculées. La Tg est en accord avec la valeur expérimentale de 118,1 °C, validant notre approche numérique pour développer un modèle pour les polymères poly-époxy.Metallization of polymer surfaces can lead to the substitution of metallic components. Polymers have lower densities and limited chemical reactivity, making them ideal candidates for the space applications. Through experiments and calculations, we studied the fundamental mechanisms of surface metallization of a poly-epoxy polymer (DGEBA/EDA). The objective of our study was to develop a non-empirical model that could take into account the mechanisms governing the nucleation and growth of thin metal films. Our group has a long experience in chemical vapor deposition, CVD, and metallization of polymer composites. But we did not applied CVD at first because of the high temperatures required in the reactor. We alternatively used ultrahigh vacuum evaporation of Cu at ambient temperature. Therefore, we make sure that atoms diffuse in the gas phase without kinetic energy. Adsorption and diffusion processes are thus closer to thermodynamic conditions that prevails in calculations. An experimental protocol was refined in order to create a chemically homogeneous polymer surface with a low roughness (Ra<1nm). The bulk and the surface of the pristine polymer were characterized (i) by Fourier Transform Infrared Spectroscopy, to determine the polymerization rate (above 90%), (ii) by differential scanning calorimetry in order to obtain the glass transition temperature (Tg) (118.1 °C), (iii) by atomic force microscopy (AFM) to calculate surface roughness (Ra ˜ 1 nm), and (iv) by X-ray photoelectron spectroscopy (XPS) to characterize surface chemical bonding. The surface was then metallized. Through AFM, the thickness of the thin film was estimated at 6 nm. We then used XPS to characterize the Cu/Poly-epoxy interfacial bonding. We deduced that Cu adsorbed preferentially on a specific oxygen atom of the polymer. To clearly identify this Cu adsorption site, we further simulated the XPS spectra of our clean or metallized polymer by quantum calculations, using a dimer model (1 molecule of DGEBA connected to 1 molecule of EDA). In the Hartree-Fock (HF) and Density Functional Theory (DFT) framework, we first simulated the XPS spectra for the pristine surface taking into account initial and final state effects. Thanks to these results, we were able to analyze the experimental spectrum with 8 contributions, leading to much more accurate results than the usual results obtained by the exclusive use of experiments and literature. We then performed classical Molecular Dynamics (MD) simulations to move from a dimer model to an amorphous polymer model. We used the general Amber force field (GAFF) and we developed a code to mimic the reticulation of monomers molecules. We started from a stoichiometric mixture of DGEBA and EDA molecules. When equilibration was reached, structural properties at 700K (e.g. distribution of bonds) were extracted from the results of the NPT simulations. From this melt of monomers, the homemade reticulation code identified and connected reactive atoms (at a pre-defined inter-atomic distance < 3Å). After each step of polymerization, the system was equilibrated at 700K (NPT simulations). After multiple reticulation/MD cycles we could achieve a polymerization rate of 93% and the Radial Distribution Function (RDF), the density and the glass transition temperature Tg were calculated. The value of the computed density was 1.115 at 300K and the calculated Tg (115.5 °C) was in good agreement with the experimental Tg of 118.1 °C, validating our numerical approach to develop a model for poly-epoxies

Absence of Dystrophin Related Protein-2 disrupts Cajal bands in a patient with Charcot-Marie-Tooth disease

Using exome sequencing in an individual with Charcot-Marie-Tooth disease (CMT) we have identified a mutation in the X-linked dystrophin-related protein 2 (DRP2) gene. A 60-year-old gentleman presented to our clinic and underwent clinical, electrophysiological and skin biopsy studies. The patient had clinical features of a length dependent sensorimotor neuropathy with an age of onset of 50 years. Neurophysiology revealed prolonged latencies with intermediate conduction velocities but no conduction block or temporal dispersion. A panel of 23 disease causing genes was sequenced and ultimately was uninformative. Whole exome sequencing revealed a stop mutation in DRP2, c.805C>T (Q269*). DRP2 interacts with periaxin and dystroglycan to form the periaxin-DRP2-dystroglycan complex which plays a role in the maintenance of the well-characterized Cajal bands of myelinating Schwann cells. Skin biopsies from our patient revealed a lack of DRP2 in myelinated dermal nerves by immunofluorescence. Furthermore electron microscopy failed to identify Cajal bands in the patient's dermal myelinated axons in keeping with ultrastructural pathology seen in the Drp2 knockout mouse. Both the electrophysiologic and dermal nerve twig pathology support the interpretation that this patient's DRP2 mutation causes characteristic morphological abnormalities recapitulating the Drp2 knockout model and potentially represents a novel genetic cause of CMT

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-alpha 2 in 10 patients: IFN-alpha 2 only in three, IFN-alpha 2 plus IFN-omega in five, and IFN-alpha 2, IFN-omega plus IFN-beta in two; IFN-omega only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-alpha 2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-omega in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-alpha 2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-. only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-omega and/or IFN-alpha 2

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population